March 26, 2021
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector strength migrated to weakness
March 25, 2021
RegMed Investors’ (RMi) closing bell: the zig and the zag, from weakness to strength in four (4) hours
March 24, 2021
RegMed Investors’ (RMi) closing bell: we are suffering from a lack of appetite for cell and gene therapy companies
March 23, 2021
RegMed Investors’ (RMi) closing bell: when you acclaim the gains, be ready for the pain
March 22, 2021
RegMed Investors’ (RMi) closing bell: through the prism of an upside markets, some cell and gene therapy equities take a mulligan
March 19, 2021
RegMed Investors’ (RMi) closing bell: sector bounces to some higher pricing
March 18, 2021
RegMed Investors’ (RMi) closing bell: falling knives draw equity blood
March 17, 2021
RegMed Investors’ (RMi) closing bell: sector pops as markets slogs higher
March 16, 2021
RegMed Investors’ (RMi) closing bell: sector retreats on low volume compressing yesterday’s gusto
March 15, 2021
RegMed Investors’ (RMi) closing bell: the sector wobbles as the market reaches new highs
March 12, 2021
RegMed Investors’ (RMi) closing bell: sector resistance rose as support degenerated
March 11, 2021
RegMed Investors’ (RMi) closing bell: stimulus bill signing elevates sector from sleeping with the fishes
March 10, 2021
RegMed Investors’ (RMi) closing bell: What went down Monday, went up Tuesday, then left Wednesday’s sector half-empty
March 9, 2021
RegMed Investors’ (RMi) closing bell: the sector, our universe of cell and gene therapy strengthened
March 8, 2021
RegMed Investors’ (RMi) closing bell: very few winners in volatile trading
March 4, 2021
RegMed Investors’ (RMi) closing bell: the hole got deeper and bottoms became steeper
March 3, 2021
RegMed Investors’ (RMi) closing bell: headwinds facilitate overheated share pricing weakness
March 2, 2021
RegMed Investors’ (RMi) closing bell: some say volatility has resurfaced, I had said it never left
March 1, 2021
RegMed Investors’ (RMi) closing bell: sector rebounds after a tough February
February 26, 2021
RegMed Investors’ (RMi) closing bell: telling a sector story with daily data
February 25, 2021
RegMed Investors’ (RMi) closing bell: the sector’s pricing vomited most upsides during frothy moves
February 24, 2021
RegMed Investors’ (RMi) closing bell: volatility provides a comeback
February 23, 2021
RegMed Investors’ (RMi) closing bell: a pullback, a reversal, a retest or in many cases just plain old earnings’ season doldrums?
February 22, 2021
RegMed Investors’ (RMi) closing bell: sector sentiment slips a steep slide
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.